Oxycodone and Tecentriq drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Oxycodone (oxycodone hydrochloride) and Tecentriq (atezolizumab). Common drug interactions include diabetic ketoacidosis among females and oedema peripheral among males.

The phase IV clinical study analyzes what interactions people have when they take Oxycodone and Tecentriq. It is created by eHealthMe based on reports of 71 people who take the same drugs from the FDA, and is updated regularly.

What is Oxycodone?

Oxycodone has active ingredients of oxycodone hydrochloride. It is often used in pain. eHealthMe is studying from 162,592 Oxycodone users. Check the latest studies of Oxycodone.

What is Tecentriq?

Tecentriq has active ingredients of atezolizumab. eHealthMe is studying from 12,796 Tecentriq users. Check the latest studies of Tecentriq.

On Jul, 14, 2026

71 people who take Oxycodone and Tecentriq together, and have interactions are studied.

Oxycodone and Tecentriq drug interactions.

What are the common drug interactions of Oxycodone and Tecentriq, by gender? *:

female:

Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
Disease progression
Dizziness
Dyspnoea (difficult or laboured respiration)
Encephalitis (inflammation of the brain)
Encephalopathy (functioning of the brain is affected by some agent or condition)
Fatigue (feeling of tiredness)
Gastric haemorrhage (bleeding stomach)
Gastrointestinal ulcer
General physical health deterioration (weak health status)

male:

Oedema peripheral (superficial swelling)
Subileus
Nausea (feeling of having an urge to vomit)
Vocal cord thickening
Disease progression
Pleural effusion (water on the lungs)
Asthenia (weakness)
Constipation
Duodenal ulcer haemorrhage (bleeding duodenal ulcer)
Duodenitis haemorrhagic (inflammation of the duodenum with bleeding disorder)

What are the common drug interactions of Oxycodone and Tecentriq, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Cystitis haemorrhagic (blood in the urine and painful voiding)
Tumour haemorrhage (bleeding from tumour)

30-39:

Death
Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)

40-49:

Encephalopathy (functioning of the brain is affected by some agent or condition)
Fatigue (feeling of tiredness)

50-59:

Oedema peripheral (superficial swelling)
Subileus
Liver disorder (liver diseases)
Pyrexia (fever)
Arthropathy
Blood pressure increased
Cholangitis (infection of the bile duct)
Decreased appetite
Diarrhoea
Disease progression

60+:

Arthritis (form of joint disorder that involves inflammation of one or more joints)
Cholangitis sclerosing (infection and obstruction of bile duct)
Aspartate aminotransferase increased
Constipation
Pleural effusion (water on the lungs)
Type 1 diabetes mellitus
Altered state of consciousness (altered state of mind)
Carotid artery stenosis (narrowing of carotid artery)
Death
Drug ineffective

What are the existing conditions these people have? *

High Blood Pressure: 19 people, 26.76%
Bronchial Carcinoma (lung cancer): 16 people, 22.54%
Lung Cancer - Small Cell (lung cancer): 12 people, 16.90%
Lung Cancer - Non-Small Cell (lung cancer): 11 people, 15.49%
Insomnia (sleeplessness): 11 people, 15.49%
Diabetes: 10 people, 14.08%
Nausea (feeling of having an urge to vomit): 8 people, 11.27%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 7 people, 9.86%
Hepatocellular Carcinoma (liver cancer): 7 people, 9.86%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 6 people, 8.45%

* Approximation only. Some reports may have incomplete information.

Do you take Oxycodone and Tecentriq?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously